ATE217197T1 - Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa - Google Patents

Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa

Info

Publication number
ATE217197T1
ATE217197T1 AT96922722T AT96922722T ATE217197T1 AT E217197 T1 ATE217197 T1 AT E217197T1 AT 96922722 T AT96922722 T AT 96922722T AT 96922722 T AT96922722 T AT 96922722T AT E217197 T1 ATE217197 T1 AT E217197T1
Authority
AT
Austria
Prior art keywords
hyaluronic acid
pct
nsaid
mucosa
diseases
Prior art date
Application number
AT96922722T
Other languages
English (en)
Inventor
Samuel Simon Asculai
Rudolf Edgar Falk
Alan Russell
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE217197T1 publication Critical patent/ATE217197T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96922722T 1995-07-18 1996-07-18 Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa ATE217197T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002154103A CA2154103C (en) 1995-07-18 1995-07-18 Treatment of mucous membrane disease, trauma or condition and for the relief of pain
PCT/CA1996/000488 WO1997003699A1 (en) 1995-07-18 1996-07-18 Use of hyaluronic acid and a nsaid for the manufacture of a medicament for the treatment of mucosal diseases

Publications (1)

Publication Number Publication Date
ATE217197T1 true ATE217197T1 (de) 2002-05-15

Family

ID=4156246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96922722T ATE217197T1 (de) 1995-07-18 1996-07-18 Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa

Country Status (10)

Country Link
US (1) US6159955A (de)
EP (1) EP0839052B1 (de)
JP (1) JP4194653B2 (de)
AT (1) ATE217197T1 (de)
AU (1) AU719257B2 (de)
CA (1) CA2154103C (de)
DE (1) DE69621132T2 (de)
ES (1) ES2176468T3 (de)
NZ (1) NZ312073A (de)
WO (1) WO1997003699A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
ATE264674T1 (de) * 1998-10-22 2004-05-15 Bioniche Life Sciences Inc Verwendung von hyaluronsäure zur behandlung der bestrahlungs-blasenentzündung
US6607745B2 (en) 2001-05-18 2003-08-19 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITBO20010361A1 (it) * 2001-06-07 2002-12-07 Farma Derma S R L Uso di acido ialuronico per la produzione di un preparato ad uso vaginale, in particolare per la cura degli stati atrofici e distrofici cerv
WO2003092629A2 (en) * 2002-05-06 2003-11-13 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating mucositis and fungal infection
TR200201556A2 (tr) * 2002-06-12 2004-01-21 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve nonsteroidal antienflamatuar içeren farmasötik bileşim
US8129359B2 (en) * 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
EP2063859B1 (de) 2006-09-13 2017-01-18 Enhance Skin Products Inc. Kosmetische zusammensetzung zur behandlung der haut und verfahren dafür
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
IT1401351B1 (it) * 2010-07-28 2013-07-18 Galsor S R L Composizione farmaceutica a base di una o più frazioni di acido ialuronico o suoi sali in associazione con un inibitore della ialuronidasi e suoi usi in campo medico
EP2543357B1 (de) * 2011-07-07 2018-03-21 Holy Stone Healthcare Co.,Ltd. Zusammensetzung zur Verwendung bei der Behandlung und Vorbeugung von entzündungsbedingten Störungen
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
JPWO2016153015A1 (ja) * 2015-03-25 2018-05-10 株式会社ファルマクリエ神戸 高分子薬効成分を含有した口腔内施用物および口腔内への高分子薬効成分の投与方法
US11684567B2 (en) * 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11633352B2 (en) 2018-01-09 2023-04-25 E2Bio Life Science, LLC Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia
US20220072030A1 (en) * 2018-12-03 2022-03-10 ASCULAI Samuel Pharmaceutical formulations and compositions suitable to treat mucositis
WO2020160344A1 (en) * 2019-02-01 2020-08-06 Ehrenpreis Eli D Diclofenac and hyaluronic acid combination treatment for oral leukpoplakia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
IN163192B (de) * 1983-10-11 1988-08-20 Fidia Spa
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
JPS63101332A (ja) * 1986-10-17 1988-05-06 Sato Seiyaku Kk 経口投与用徐放性製剤
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2951681B2 (ja) * 1990-02-23 1999-09-20 株式会社資生堂 経粘膜投与用薬剤組成物
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US6017900A (en) * 1991-07-03 2000-01-25 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and nsaids
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
JPH0717870A (ja) * 1993-06-29 1995-01-20 Toshiko Yamamoto トローチ剤

Also Published As

Publication number Publication date
CA2154103C (en) 1998-02-24
AU6351996A (en) 1997-02-18
EP0839052B1 (de) 2002-05-08
WO1997003699A1 (en) 1997-02-06
JP4194653B2 (ja) 2008-12-10
US6159955A (en) 2000-12-12
DE69621132D1 (de) 2002-06-13
AU719257B2 (en) 2000-05-04
DE69621132T2 (de) 2002-10-31
NZ312073A (en) 2000-02-28
JPH11514967A (ja) 1999-12-21
CA2154103A1 (en) 1997-01-19
ES2176468T3 (es) 2002-12-01
EP0839052A1 (de) 1998-05-06

Similar Documents

Publication Publication Date Title
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE256475T1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE69417733D1 (de) Verfahren zur hemmung des knochenschwundes mit 3,4-diarylchroman
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69903750D1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
ATE146677T1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
ATE309795T1 (de) Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE249828T1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
ATE259234T1 (de) Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
FI971127A (fi) 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen
HUP9902135A2 (hu) (+)-alfa-(2,3-Dimetoxi-fenil)-1-[2-(4-fluor-fenil)-etil]-4-piperidin-metanol alkalmazása depresszív és bipoláris rendellenességek kezelésére alkalmas gyógyszerkészítmény előállítására
ATE243521T1 (de) Verwendung von biopolymeren zur behandlung der muskeln
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit